Although IL-6 is a proinflammatory mediator, the use of tocilizumab, a recombinant humanized anti-IL-6 biologic, in psoriasis led to unpredictable results.26, 27 Studies that evaluated the inflammatory environment of the skin failed to include IL-6 expression in the main pathogenic pathway of psoriasis. This evidence concerns the gene IL6 and psoriasis.